Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMURF1 | Q9HCE7 | 5/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037241 | 0.87 | MAPT (0.43) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL20162730 | 0.87 | MAPT (0.43) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL2219241 | 0.84 | HTT (0.65) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL17324829 | 0.84 | MAPT (0.64) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL30038081 | 0.84 | HTT (0.65) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL30153810 | 0.83 | MAPT (0.49) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL20162908 | 0.81 | GAA (0.51) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL30036841 | 0.81 | GAA (0.51) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL17321491 | 0.81 | MAPT (0.47) | MAPTHTTSMURF1METNPSR1 | |
| SCHEMBL19997265 | 0.81 | PTGS2 (0.51) | MAPTHTTSMURF1METNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | MAPT 4877/4885HTT 4294/4885SMURF1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.